Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development

Autolus Therapeutics plc

Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.
Net proceeds to fund obe-cel clinical development, manufacturing, and commercial infrastructure.
Additionally expects $250 million from BioNTech under license/option agreement and private placement.
Offering expected to close February 12, 2024; Jefferies and Truist are joint bookrunners.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Autolus Therapeutics plc entered into Underwriting Agreement with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein valued at $350 million (effective 2024-02-08).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein
Value: $350 million
Effective: 2024-02-08

Exact text from the filing

On February 8, 2024, Autolus Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein (the “ Underwriters ”), in connection with the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) by the Company of 58,333,336 American Depositary Shares (“ ADSs ”) representing 58,333,336 ordinary shares of the Company at an offering price of $6.00 per ADS. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $350 million.

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-24-028372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.